Lack of Association between 5α-Reductase Inhibitors and Depression.

Area of Science:

• Pharmacology and Therapeutics
• Mental Health Research
• Urology

Background:

• Post-marketing surveillance indicated potential depression risk with 5α-reductase inhibitors (finasteride, dutasteride).
• Depression risk was added to finasteride labeling due to these concerns.
• Existing peer-reviewed studies on this topic have yielded limited and conflicting findings.

Purpose of the Study:

• To investigate the association between 5α-reductase inhibitor exposure and the risk of depression.
• To evaluate depression risk using sequence symmetry analysis in a large patient cohort.

Main Methods:

• Utilized National Veterans Health Administration administrative data from fiscal year 2014.
• Identified 53,848 male patients initiating 5α-reductase inhibitor therapy.
• Assessed incident depression via antidepressant prescription and diagnosis, comparing pre- and post-initiation periods using symmetry ratios. Included a counterfactual analysis with α1-adrenergic receptor antagonists.

Main Results:

• No increased incidence of antidepressant prescribing or depression diagnosis was observed following 5α-reductase inhibitor initiation (SR 0.84 and 0.83, respectively).
• Stratification by various factors (age, drug, antidepressant class, prior exposure) did not reveal a positive association.
• An α1-adrenergic receptor antagonist analysis yielded similar null results (SR 0.87).

Conclusions:

• Initiation of 5α-reductase inhibitors is not associated with an elevated risk of depression.
• Findings suggest that depression in patients using these drugs may be more related to underlying benign prostatic hyperplasia and its symptoms rather than the medication itself.